Clenbuterol hydrochloride | C12H19Cl3N2O - PubChem

Clenbuterol

clenbuterol melting point

The risk or severity of adverse effects can be increased when Trimipramine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Fenoterol is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol. The therapeutic efficacy of Acemetacin can be decreased when used in combination with Clenbuterol. The risk or severity of adverse effects can be increased when Procaterol is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Clomipramine is combined with Clenbuterol. Beta 2 -adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia.

Clenbuterol Specification

Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats. Clenbuterol is being used alone and in conjunction with other substances to promote the growth of skeletal muscle 'anabolic effects' and to reduce body fat 'catabolic effects'. The risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Rasagiline is combined with Clenbuterol. SKIN May cause skin irritation.

This receptor binds epinephrine and norepinephrine with approximately e The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Beta-3 is involved in the regulation of lipolysis and thermogenesis. General Function Receptor signaling protein activity Specific Function Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems.

NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res Brain Res Rev. No indication for a positive effect]. Pharmacological modulation of nerve growth factor synthesis: Brain Res Mol Brain Res. Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats.

It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res. Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation.

Epub Feb Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust. Am J Vet Res. Clenbuterol affects the expression of messenger RNA for interleukin 10 in peripheral leukocytes from horses challenged intrabronchially with lipopolysaccharides. General Function Vitamin d hydroxylase activity Specific Function Cytochromes P are a group of heme-thiolate monooxygenases.

It oxidizes a variety of structurally un Epub Nov General Function Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen Specific Function Cytochromes P are a group of heme-thiolate monooxygenases.

A Beta-2 adrenergic receptor. U Beta-1 adrenergic receptor. U Beta-3 adrenergic receptor. U Beta-nerve growth factor.

U Tumor necrosis factor. The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Acebutolol is combined with Clenbuterol. The therapeutic efficacy of Acemetacin can be decreased when used in combination with Clenbuterol.

The risk or severity of adverse effects can be increased when Amineptine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Amoxapine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Amphetamine is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Atosiban. The risk or severity of adverse effects can be increased when Benmoxin is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Benzphetamine is combined with Clenbuterol. The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Betahistine. The risk or severity of adverse effects can be increased when Brofaromine is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Bucindolol. The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Caroxazone is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Celiprolol. The risk or severity of adverse effects can be increased when Clenbuterol is combined with Chlorphentermine. The risk or severity of adverse effects can be increased when Clomipramine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.

The serum concentration of Clenbuterol can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Dibenzepin is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Dobutamine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Dopamine is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Doxepin is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Clenbuterol is combined with Doxofylline.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Epanolol. The risk or severity of adverse effects can be increased when Ephedrine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Epinephrine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Clenbuterol is combined with Etilefrine.

The risk or severity of adverse effects can be increased when Fenoterol is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Clenbuterol is combined with Fenozolone. The risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Harmaline is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Hydroxyamphetamine. The risk or severity of adverse effects can be increased when Imipramine is combined with Clenbuterol. The therapeutic efficacy of Iobenguane can be decreased when used in combination with Clenbuterol. The risk or severity of adverse effects can be increased when Iprindole is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Iproclozide is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Iproniazid is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Isoprenaline is combined with Clenbuterol.

The risk or severity of adverse effects can be increased when Clenbuterol is combined with Isoxsuprine. May cause respiratory tract irritation. The most important action of clenbuterol and other beta2-agonists in the lung is relaxation of airway smooth muscle.

For this reason, such drugs are widely used for relief of bronchospasm in human asthma and similar diseases in animals. When these drugs bind to b2-adrenoceptors, they activate adenylyl cyclase, which leads to an increase in the intracellular concentration of the second messenger cyclic adenosine monophosphate cAMP and activation of protein kinase A PKA.

In the tracheobronchial tree and in the uterus, b2-agonists, cAMP, and PKA inhibit smooth muscle contraction by opening K1 channels and by down-regulation of myosin light chain kinase activity. Clenbuterol is classed as a 'beta-2 agonist' and its short-term effects are similar to stimulant drugs like amphetamine or ephedrine i.

The main therapeutic use of clenbuterol is in the treatment of asthma to relax the smooth muscle in the airways. Clenbuterol is also used as a bronchodilator in veterinary medicine. Clenbuterol produced for human consumption is generally in tablet form.

The most common veterinarian preparation is a syrup. Clenbuterol is being used alone and in conjunction with other substances to promote the growth of skeletal muscle 'anabolic effects' and to reduce body fat 'catabolic effects'.

Some athletes and body builders are using clenbuterol without proof of its effectiveness or safety. Some animal studies have shown that using a stimulant like clenbuterol has the 'anabolic effect' of increasing muscle mass and body weight by enhancing muscle protein synthesis in rodents.

Iamges: clenbuterol melting point

clenbuterol melting point

The risk or severity of adverse effects can be increased when Amphetamine is combined with Clenbuterol. For example, it can produce 2-tert-butylamino 3,5-dichloronitro-phenyl -ethanol and 2-tert-butylamino 3,5-dichloronitroso-phenyl -ethanol.

clenbuterol melting point

The risk or severity of adverse effects can be increased when Nortriptyline is combined with Clenbuterol. The risk or severity of adverse effects can be increased when Phenylephrine is combined with Clenbuterol.

clenbuterol melting point

Beta 2 -adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia. The risk or severity of adverse effects can be increased when Dobutamine is combined with Clenbuterol. Stable under normal conditions. The risk or severity of adverse effects can be increased when Midodrine dianabol y winstrol oral combined with Clenbuterol. The risk or severity of adverse effects can be increased when Metaraminol is combined with Clenbuterol. It is mainly secreted by macrophages and can induce cell death of certain tumor clenbuterol melting point lines. Neuroprotection mediated via neurotrophic factors and induction clenbuterol melting point neurotrophic factors.